PBYI NASDAQ
Puma Biotechnology, Inc.
1W: +6.3%
1M: +11.1%
3M: +36.1%
YTD: +88.0%
1Y: +115.3%
3Y: +359.8%
5Y: +83.3%
$10.92
+0.07 (+0.65%)
After Hours: $11.38 (+0.46, +4.26%)
Weekly Expected Move ±6.4%
$10
$10
$11
$12
$12
Credit Risk of going bust: lower than 76% of companies Debt: 0.9% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down 99.9%), Puma Biotechnology, Inc. would be worth roughly what it owes.
Total debt $4.8M against a stock market value of $560.1M.
Distance to default 8.78 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $2.4M (short-term plus half of long-term), stock volatility 60.8%; Altman Z'' -14.50. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down 99.9%), Puma Biotechnology, Inc. would be worth roughly what it owes.
Total debt $4.8M against a stock market value of $560.1M.
Distance to default 8.78 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $2.4M (short-term plus half of long-term), stock volatility 60.8%; Altman Z'' -14.50. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
2 relationships2
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2022-09-22
Earliest Filing
2022-09-22
Latest Filing
partner: 2
Counterparties (Filed by PBYI)
2 relationshipsCompanies named in PBYI's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Millennium Pharmaceuticals, Inc. | — | partner | Granted exclusive license rights to Puma Biotechnology, Inc. for alisertib products | 2022-09-22 | View |
| Takeda Pharmaceutical Company Limited | TKPHF | partner | Parent company of Millennium Pharmaceuticals, Inc. and licensor of intellectual property rights | 2022-09-22 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-06-16 | Shareholder Vote | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-24 | Amendments to Articles of Incorporation or Bylaws; Financial Statements and Exhibits | View | |
| 2025-06-13 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-09 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-27 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-11-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-09-16 | Other Events | View | |
| 2024-08-15 | Other Events | View | |
| 2024-08-07 | Other Events | View | |
| 2024-08-01 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-06-24 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2024-05-17 | Other Events | View | |
| 2024-05-02 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-03-19 | Other Events | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR